STAT3 and lung carcinoma: Inactivation of STAT3 is a target for increasing cisplatin sensitivity in lung cancer treatment, galangin, and laricitrin are STAT3 inhibitors in adjuvant chemotherapy (Chang et al., 2016a; Chang et al., 2016b; Yu et al., 2018).